Brian Abrahams Analyst Performance

Analyst at Royal Bank Of Canada

Brian Abrahams is a stock analyst at Royal Bank Of Canada focused in the medical sector, covering 42 publicly traded companies. Over the past year, Brian Abrahams has issued 97 stock ratings, including buy, hold, and sell recommendations. While full access to Brian Abrahams' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brian Abrahams' coverage history, rating activity, and performance tendencies â€” helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 295 Last 11 Years
Buy Recommendations: 64.63% 190 Buy Ratings
Companies Covered: 42 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	64.6%	190 ratings
Hold	35.0%	103 ratings
Sell	0.3%	1 ratings

Out of 294 total stock ratings issued by Brian Abrahams at Royal Bank Of Canada, the majority (64.6%) have been Buy recommendations, followed by 35.0% Hold and 0.3% Sell.

Best & Worst Calls

Best Call
0000.0%
SAGE
Apr 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
SRPT
Feb 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	95.2% of companies on NASDAQ	40 companies
NYSE	4.8% of companies on NYSE	2 companies

Brian Abrahams, an analyst at Royal Bank Of Canada, currently covers 42 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 41 companies	97.6%
	Manufacturing 1 company	2.4%

Brian Abrahams of Royal Bank Of Canada specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 31 companies	73.8%
MED - DRUGS 5 companies	11.9%
BIOTECHNOLOGY 2 companies	4.8%
PHARMACEUTICAL PREPARATIONS 2 companies	4.8%
Miscellaneous 1 company	2.4%
MED - OUTP/HM CRE 1 company	2.4%

About Brian Abrahams

Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 15 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co. He is a licensed non-practicing physician and holds a medical degree from the Albert Einstein College of Medicine. He did his undergraduate studies at Yale University, where he graduated magna cum laude with a Bachelor of Science degree in Molecular Biophysics & Biochemistry.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
GILD Gilead Sciences	6/8/2026	Reiterated Rating	$129.17		Sector Perform
APGE Apogee Therapeutics	6/8/2026	Boost Price Target	$86.92	$97.00	Sector Perform
GILD Gilead Sciences	6/1/2026	Reiterated Rating	$134.43	$122.00	Overweight
GILD Gilead Sciences	6/1/2026	Upgrade	$131.10		Moderate Buy
NBIX Neurocrine Biosciences	5/29/2026	Boost Price Target	$157.47	$183.00	Outperform
BIIB Biogen	5/27/2026	Boost Price Target	$193.08	$227.00	Outperform
REGN Regeneron Pharmaceuticals	5/18/2026	Lower Price Target	$623.32	$707.00	Sector Perform
GILD Gilead Sciences	5/8/2026	Lower Price Target	$130.55	$122.00	Sector Perform
PTCT PTC Therapeutics	5/8/2026	Boost Price Target	$79.08	$82.00	Sector Perform
XENE Xenon Pharmaceuticals	5/8/2026	Boost Price Target	$55.89	$82.00	Outperform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
NBIX Neurocrine Biosciences	5/6/2026	Boost Price Target	$144.90	$180.00	Outperform
VRTX Vertex Pharmaceuticals	5/5/2026	Boost Price Target	$429.85	$543.00	Outperform
BIIB Biogen	4/30/2026	Boost Price Target	$191.32	$222.00	Outperform
REGN Regeneron Pharmaceuticals	4/30/2026	Lower Price Target	$707.09	$762.00	Sector Perform
BIIB Biogen	4/29/2026	Boost Price Target	$191.58	$222.00	Outperform
DMRA Damora Therapeutics, Inc. Common Stock	4/24/2026	Initiated Coverage	$25.42	$40.00	Outperform
DMRA Damora Therapeutics, Inc. Common Stock	4/23/2026	Upgrade	$24.75		Moderate Buy
EVMN Evommune	4/10/2026	Reiterated Rating	$27.56	$48.00	Outperform
PHVS Pharvaris	4/6/2026	Lower Price Target	$28.56	$51.00	Outperform
PHVS Pharvaris	3/9/2026	Initiated Coverage	$26.63	$52.00	Outperform
APGE Apogee Therapeutics	3/2/2026	Lower Price Target	$70.92	$82.00	Sector Perform
AARD Aardvark Therapeutics	3/2/2026	Downgrade	$12.49	$6.00	Sector Perform
REGN Regeneron Pharmaceuticals	3/2/2026	Boost Price Target	$784.09	$765.00	Sector Perform
MLTX MoonLake Immunotherapeutics	3/2/2026	Boost Price Target	$17.69	$13.00	Sector Perform
KYMR Kymera Therapeutics	2/26/2026	Reiterated Rating	$91.56	$108.00	Outperform
ACAD ACADIA Pharmaceuticals	2/26/2026	Lower Price Target	$24.82	$30.00	Outperform
LKFT Lakefront Biotherapeutics American Depositary Shares	2/24/2026	Boost Price Target	$34.36	$33.00	Sector Perform
PTCT PTC Therapeutics	2/20/2026	Lower Price Target	$69.90	$82.00	Sector Perform
MLTX MoonLake Immunotherapeutics	2/20/2026	Boost Price Target	$17.86	$12.00	Sector Perform
PRTA Prothena	2/20/2026	Boost Price Target	$8.83	$12.00	Sector Perform
VRTX Vertex Pharmaceuticals	2/13/2026	Lower Price Target	$496.69	$541.00	Outperform
NBIX Neurocrine Biosciences	2/12/2026	Lower Price Target	$126.01	$177.00	Outperform
GILD Gilead Sciences	2/11/2026	Boost Price Target	$156.39	$118.00	Sector Perform
INCY Incyte	2/11/2026	Lower Price Target	$98.59	$92.00	Sector Perform
BIIB Biogen	2/9/2026	Boost Price Target	$201.18	$233.00	Outperform
ACAD ACADIA Pharmaceuticals	2/3/2026	Lower Price Target	$26.13	$31.00	Outperform
BCRX BioCryst Pharmaceuticals	1/30/2026	Lower Price Target	$6.44	$13.00	Outperform
NRIX Nurix Therapeutics	1/29/2026	Boost Price Target	$17.60	$30.00	Outperform
GHRS GH Research	1/23/2026	Boost Price Target	$16.46	$40.00	Outperform
DFTX Definium Therapeutics	1/23/2026	Boost Price Target	$17.29	$36.00	Outperform
CODE RED: AI Meltdown Imminent? (Ad) After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. See the five simple steps to prepare before it's too late
APGE Apogee Therapeutics	1/22/2026	Downgrade	$81.91	$83.00	Sector Perform
VRTX Vertex Pharmaceuticals	1/22/2026	Upgrade	$461.14	$546.00	Outperform
GILD Gilead Sciences	1/20/2026	Boost Price Target	$124.91	$103.00	Sector Perform
BIIB Biogen	1/13/2026	Reiterated Rating	$178.30		Outperform
GILD Gilead Sciences	1/8/2026	Lower Price Target	$121.35	$100.00	Sector Perform
SRPT Sarepta Therapeutics	1/8/2026	Boost Price Target	$21.31	$18.00	Sector Perform
APGE Apogee Therapeutics	1/6/2026	Reiterated Rating	$78.59		Outperform
KYMR Kymera Therapeutics	12/16/2025	Boost Price Target	$85.68	$103.00	Outperform
NBIX Neurocrine Biosciences	12/8/2025	Boost Price Target	$159.46	$180.00	Outperform
PTCT PTC Therapeutics	12/1/2025	Downgrade	$85.99	$91.00	Sector Perform
NMRA Neumora Therapeutics	12/1/2025	Upgrade	$2.26	$7.00	Outperform
SION Sionna Therapeutics	12/1/2025	Reiterated Rating	$43.57	$24.00	Underperform
CTNM Contineum Therapeutics	11/21/2025	Lower Price Target	$11.08	$22.00	Outperform
CDTX Cidara Therapeutics	11/17/2025	Downgrade	$217.78		Sector Perform
AARD Aardvark Therapeutics	11/14/2025	Lower Price Target	$10.86	$18.00	Outperform
CRBP Corbus Pharmaceuticals	11/13/2025	Lower Price Target	$11.09	$53.00	Outperform
PRTA Prothena	11/7/2025	Boost Price Target	$10.15	$11.00	Sector Perform
DFTX Definium Therapeutics	11/7/2025	Lower Price Target	$11.26	$20.00	Outperform
LKFT Lakefront Biotherapeutics American Depositary Shares	11/7/2025	Boost Price Target	$31.38	$32.00	Sector Perform
CDTX Cidara Therapeutics	11/7/2025	Boost Price Target	$99.95	$145.00	Outperform
ACAD ACADIA Pharmaceuticals	11/6/2025	Lower Price Target	$21.35	$32.00	Outperform
PTCT PTC Therapeutics	11/5/2025	Boost Price Target	$72.90	$82.00	Outperform
XENE Xenon Pharmaceuticals	11/4/2025	Boost Price Target	$39.54	$58.00	Outperform
VRTX Vertex Pharmaceuticals	11/4/2025	Lower Price Target	$430.41	$415.00	Sector Perform
KPTI Karyopharm Therapeutics	11/4/2025	Lower Price Target	$5.66	$19.00	Outperform
APGE Apogee Therapeutics	11/3/2025	Boost Price Target	$57.13	$70.00	Outperform
BIIB Biogen	10/31/2025	Lower Price Target	$149.61	$210.00	Outperform
GILD Gilead Sciences	10/31/2025	Boost Price Target	$120.73	$105.00	Sector Perform
INCY Incyte	10/29/2025	Boost Price Target	$89.19	$84.00	Sector Perform
REGN Regeneron Pharmaceuticals	10/29/2025	Boost Price Target	$654.96	$708.00	Sector Perform
NBIX Neurocrine Biosciences	10/29/2025	Boost Price Target	$139.82	$160.00	Outperform
LKFT Lakefront Biotherapeutics American Depositary Shares	10/22/2025	Boost Price Target	$32.33	$28.00	Sector Perform
BIIB Biogen	10/8/2025	Lower Price Target	$152.21	$217.00	Outperform
GILD Gilead Sciences	10/8/2025	Boost Price Target	$116.78	$100.00	Sector Perform
SRPT Sarepta Therapeutics	10/8/2025	Boost Price Target	$24.02	$16.00	Sector Perform
MLTX MoonLake Immunotherapeutics	9/29/2025	Reiterated Rating	$6.86	$10.00	Sector Perform
APGE Apogee Therapeutics	9/25/2025	Initiated Coverage	$38.42	$60.00	Outperform
CDTX Cidara Therapeutics	9/24/2025	Set Price Target	$88.16	$137.00	Outperform
INCY Incyte	9/24/2025	Boost Price Target	$84.54	$81.00	Sector Perform
KYMR Kymera Therapeutics	9/16/2025	Initiated Coverage	$47.28	$70.00	Outperform
NBIX Neurocrine Biosciences	9/5/2025	Boost Price Target	$143.76	$149.00	Outperform
SION Sionna Therapeutics	9/3/2025	Initiated Coverage	$25.39	$22.00	Sector Perform
XENE Xenon Pharmaceuticals	9/2/2025	Reiterated Rating	$39.12	$55.00	Outperform
AARD Aardvark Therapeutics	8/14/2025	Lower Price Target	$11.44	$19.00	Outperform
XENE Xenon Pharmaceuticals	8/12/2025	Lower Price Target	$36.96	$55.00	Outperform
PTCT PTC Therapeutics	8/8/2025	Reiterated Rating	$46.87	$63.00	Outperform
ETNB 89BIO	8/8/2025	Lower Price Target	$8.92	$11.00	Sector Perform
GILD Gilead Sciences	8/8/2025	Boost Price Target	$119.21	$98.00	Sector Perform
ACAD ACADIA Pharmaceuticals	8/7/2025	Boost Price Target	$23.84	$40.00	Outperform
VRTX Vertex Pharmaceuticals	8/5/2025	Lower Price Target	$389.93	$405.00	Sector Perform
The REAL Reason Trump is Invading Iran (Ad) For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
PRTA Prothena	8/5/2025	Lower Price Target	$7.28	$10.00	Sector Perform
REGN Regeneron Pharmaceuticals	8/4/2025	Boost Price Target	$569.71	$695.00	Sector Perform
BIIB Biogen	8/1/2025	Boost Price Target	$126.28	$219.00	Outperform
NBIX Neurocrine Biosciences	7/31/2025	Lower Price Target	$129.41	$144.00	Outperform
INCY Incyte	7/30/2025	Boost Price Target	$77.88	$72.00	Sector Perform
SRPT Sarepta Therapeutics	7/17/2025	Lower Price Target	$21.46	$23.00	Sector Perform
BCRX BioCryst Pharmaceuticals	6/30/2025	Reiterated Rating	$9.23	$13.00	Outperform
BIIB Biogen	6/25/2025	Set Price Target	$126.16	$213.00	Outperform
CDTX Cidara Therapeutics	6/24/2025	Upgrade	$49.86	$75.00	Moderate Buy
ACAD ACADIA Pharmaceuticals	6/23/2025	Boost Price Target	$22.12	$38.00	Outperform
VRTX Vertex Pharmaceuticals	6/17/2025	Set Price Target	$448.47	$420.00	Sector Perform
REGN Regeneron Pharmaceuticals	5/27/2025	Reiterated Rating	$599.20	$662.00	Sector Perform
CTNM Contineum Therapeutics	5/15/2025	Reiterated Rating	$3.72	$31.00	Outperform
KPTI Karyopharm Therapeutics	5/13/2025	Lower Price Target	$5.40	$33.00	Outperform
XENE Xenon Pharmaceuticals	5/13/2025	Lower Price Target	$29.93	$55.00	Outperform
CRBP Corbus Pharmaceuticals	5/7/2025	Lower Price Target	$6.34	$58.00	Outperform
VRTX Vertex Pharmaceuticals	5/6/2025	Boost Price Target	$434.64	$423.00	Sector Perform
BCRX BioCryst Pharmaceuticals	5/6/2025	Reiterated Rating	$10.40	$13.00	Outperform
BIIB Biogen	5/2/2025	Lower Price Target	$122.38	$205.00	Outperform
INCY Incyte	4/30/2025	Boost Price Target	$61.11	$67.00	Sector Perform
REGN Regeneron Pharmaceuticals	4/30/2025	Lower Price Target	$586.51	$943.00	Outperform
LEGN Legend Biotech	4/22/2025	Reiterated Rating	$33.48	$84.00	Outperform
BIIB Biogen	4/22/2025	Boost Price Target	$117.63	$225.00	Outperform
NBIX Neurocrine Biosciences	4/14/2025	Upgrade	$90.87	$137.00	Outperform
BCRX BioCryst Pharmaceuticals	4/11/2025	Reiterated Rating	$6.55	$11.00	Outperform
VRTX Vertex Pharmaceuticals	4/1/2025	Boost Price Target	$487.06	$420.00	Sector Perform
SRPT Sarepta Therapeutics	3/31/2025	Downgrade	$70.41	$87.00	Sector Perform
MLTX MoonLake Immunotherapeutics	3/18/2025	Initiated Coverage	$38.67	$67.00	Outperform
AARD Aardvark Therapeutics	3/10/2025	Initiated Coverage	$10.13	$21.00	Outperform
GHRS GH Research	3/7/2025	Initiated Coverage	$10.55	$31.00	Outperform
SRPT Sarepta Therapeutics	2/27/2025	Lower Price Target	$107.24	$161.00	Outperform
BCRX BioCryst Pharmaceuticals	2/25/2025	Reiterated Rating	$8.11	$11.00	Outperform
PRTA Prothena	2/21/2025	Lower Price Target	$15.61	$20.00	Sector Perform
VRTX Vertex Pharmaceuticals	2/20/2025	Boost Price Target	$475.68	$408.00	Sector Perform
KPTI Karyopharm Therapeutics	2/20/2025	Reiterated Rating	$9.41	$45.00	Outperform
BIIB Biogen	2/13/2025	Lower Price Target	$135.56	$225.00	Outperform
GILD Gilead Sciences	2/12/2025	Boost Price Target	$103.52	$90.00	Sector Perform
INCY Incyte	2/11/2025	Lower Price Target	$68.30	$68.00	Sector Perform
VRTX Vertex Pharmaceuticals	2/11/2025	Boost Price Target	$459.15	$407.00	Sector Perform
PLRX Pliant Therapeutics	2/10/2025	Downgrade	$7.79	$4.00	Sector Perform
KPTI Karyopharm Therapeutics	2/10/2025	Reiterated Rating	$9.77	$45.00	Outperform
NBIX Neurocrine Biosciences	2/7/2025	Lower Price Target	$122.00	$148.00	Sector Perform
GILD Gilead Sciences	2/3/2025	Reiterated Rating	$99.12	$84.00	Sector Perform
AXSM Axsome Therapeutics	1/29/2025	Reiterated Rating	$104.53	$139.00	Outperform

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brian Abrahams Analyst Performance

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

About Brian Abrahams

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brian Abrahams Analyst Performance

Analyst Rankings, Coverage, and Performance Statistics

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

About Brian Abrahams

Brian Abrahams' Ratings History at Royal Bank Of Canada

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools